Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amicus Therapeutics (NQ: FOLD ) 11.42 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amicus Therapeutics < Previous 1 2 3 4 5 Next > Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 October 28, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug October 17, 2024 Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... Via Benzinga Topics Intellectual Property Lawsuit Exposures Financial Intellectual Property Legal Travelers Posts Upbeat Results, Joins Iridium Communications, Snap-on And Other Big Stocks Moving Higher On Thursday October 17, 2024 Via Benzinga Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva October 17, 2024 Company Grants Teva a License to Market Generic Galafold® Beginning in January 2037 From Amicus Therapeutics, Inc. Via GlobeNewswire Expert Outlook: Amicus Therapeutics Through The Eyes Of 4 Analysts October 11, 2024 Via Benzinga Amicus Therapeutics Announces Participation at the World Muscle Society Annual Congress 2024 October 04, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Investors to Contact the Firm September 17, 2024 From Kaskela Law LLC Via Business Wire UPDATE -- Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 September 03, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 September 03, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts May 14, 2024 Via Benzinga Amicus Therapeutics Announces Participation at the SSIEM 2024 Annual Symposium September 03, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2024 August 30, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates August 08, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024 July 30, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product June 04, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire This Boston Beer Analyst Turns Bullish; Here Are Top 5 Upgrades For Today. May 14, 2024 Via Benzinga FOLD Stock Earnings: Amicus Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 FOLD stock results show that Amicus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates May 09, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference May 08, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 May 01, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report March 20, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Stock Sees RS Rating Improve To 74 March 05, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. Via Investor's Business Daily Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024 March 01, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates February 28, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024 February 15, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Stock Sees Improved Relative Strength Rating February 09, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. Via Investor's Business Daily Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™ February 08, 2024 - Award Recognizes Approval of Amicus Therapeutics’ Two-component Therapy for the Treatment of Late-onset Pompe Disease - From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024 February 01, 2024 From Amicus Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
